Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

A new liver transplant priority for patients with hepatocellular carcinoma.

Ravaioli M, Grazi GL, Vetrone G, Kimura T, Zanello M, Ercolani G, Cescon M, Varotti G, Del Gaudio M, Tuci F, Cucchetti A, La Barba G, Vivarelli M, Lauro A, Ramacciato G, Pinna AD.

Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1742-5.

PMID:
19102382
2.

Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?

Cuomo O, Perrella A, Arenga G.

Transplant Proc. 2008 Jul-Aug;40(6):1906-9. doi: 10.1016/j.transproceed.2008.05.072.

PMID:
18675085
3.

Survival benefit after liver transplantation: a single European center experience.

Ravaioli M, Grazi GL, Dazzi A, Bertuzzo V, Ercolani G, Cescon M, Cucchetti A, Masetti M, Ramacciato G, Pinna AD.

Transplantation. 2009 Sep 27;88(6):826-34. doi: 10.1097/TP.0b013e3181b26807.

PMID:
19920783
4.

Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.

Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W.

Liver Transpl. 2003 Jun;9(6):557-63.

5.

A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.

Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L.

Liver Transpl. 2007 Jun;13(6):857-66.

6.

Laboratory test variability and model for end-stage liver disease score calculation: effect on liver allocation and proposal for adjustment.

Ravaioli M, Masetti M, Ridolfi L, Capelli M, Grazi GL, Venturoli N, Di Benedetto F, Bianchi FB, Cavrini G, Faenza S, Begliomini B, Pinna AD, Gerunda GE, Ballardini G.

Transplantation. 2007 Apr 15;83(7):919-24.

PMID:
17460563
7.
8.

Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.

Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G.

Liver Transpl. 2004 Mar;10(3):449-55.

9.

The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.

Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM; ESLD-HIV Working Group Investigators.

Liver Transpl. 2009 Sep;15(9):1133-41. doi: 10.1002/lt.21735.

10.

Liver transplantation for hepatocellular carcinoma: results of a multicenter study with common priorization criteria.

Santoyo J, Sanchez B, de la Mata M, Fernández-Aguilar JL, Lopez-Ciller P, Pascasio JM, Suarez MA, Gomez MA, Nogueras F, Muffak K, Cuende N, Alonso M.

Transplant Proc. 2009 Apr;41(3):1009-11. doi: 10.1016/j.transproceed.2009.02.028.

PMID:
19376412
11.
12.

Waiting list removal rates among patients with chronic and malignant liver diseases.

Freeman RB, Edwards EB, Harper AM.

Am J Transplant. 2006 Jun;6(6):1416-21.

13.

The outcome of surgical resection versus assignment to the liver transplant waiting list for hepatocellular carcinoma.

Pierie JP, Muzikansky A, Tanabe KK, Ott MJ.

Ann Surg Oncol. 2005 Jul;12(7):552-60. Epub 2005 May 9.

PMID:
15889217
14.

Liver transplantation for hepatocellular carcinoma in New Zealand: a prospective intent-to-treat analysis.

Marui Y, McCall J, Gane E, Holden A, Duncan D, Yeong ML, Chow K, Munn S.

N Z Med J. 2005 Jun 24;118(1217):U1532.

PMID:
15980906
15.

Analysis of Model for End-Stage Liver Disease (MELD) score in a liver transplantation waiting list.

Ferraz-Neto BH, Hidalgo R, Thomé T, Melo VA Jr, Lobue A, Zurstrassen MP, Moraes JM Jr, Meira-Filho SP, Rezende MB, Fonseca LE, Pandullo FL, Soeiro FS, Afonso RC.

Transplant Proc. 2007 Oct;39(8):2511-3.

PMID:
17954160
16.

The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.

Freitas AC, Itikawa WM, Kurogi AS, Stadnik LG, Parolin MB, Coelho JC.

Arq Gastroenterol. 2010 Jul-Sep;47(3):233-7.

17.

Deaths on the liver transplant waiting list: an analysis of competing risks.

Kim WR, Therneau TM, Benson JT, Kremers WK, Rosen CB, Gores GJ, Dickson ER.

Hepatology. 2006 Feb;43(2):345-51.

PMID:
16440361
18.

Preliminary results of liver transplantation for hepatocellular carcinoma among allocation organ policy strategies, neoadjuvant treatments, and intention-to-treat analysis.

Andorno E, Bottino G, Morelli N, Casaccia M, Gelli M, Piredda D, Immordino G, Ferrante R, Nardi I, Troilo BM, Di Domenico S, Ravazzoni F, Valente U.

Transplant Proc. 2008 Jul-Aug;40(6):1972-3. doi: 10.1016/j.transproceed.2008.05.061.

PMID:
18675103
19.

Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.

Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V.

Am J Transplant. 2006 Aug;6(8):1957-62. Epub 2006 Jun 9.

20.

Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation.

Vargas V, Rimola A, Casanovas T, Castells L, Navasa M, Baliellas C, Bilbao I, Visa J, Jaurrieta E, Margarit C.

Transpl Int. 2003 Apr;16(4):270-5. Epub 2003 Feb 21.

PMID:
12730808

Supplemental Content

Support Center